Program
maridebart cafraglutide
Also written as “Maridebart cafraglutide”, “Maridebart Cafraglutide” and “AMG 133”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Atherosclerosis · Sleep Apnea, Obstructive · Liver Diseases, led by Amgen.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 3219 open or running | phase 3since Feb 28, 2025 | Jul 16, 2020 | Nov 18, 2026phase 1 · NCT07523711 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Jul 16, 2020.
- Aug 29, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07160257 · 56 enrolled · United States
- Nov 5, 20252 phase 3 studiesNCT07225686, NCT07226765
- Nov 7, 20252 phase 1 studies in OverweightNCT07226778, NCT07229157
- Dec 16, 20252 phase 1 studies in OverweightNCT07310563, NCT07313761
- Feb 6, 2026Phase 2 study in OverweightNCT07441252 · 180 enrolled · United States
- Feb 18, 20263 phase 1 studiesNCT07429045, NCT07429032, NCT07428525
- Apr 6, 2026Phase 1 study in OverweightNCT07523711 · 49 enrolled · United States
- May 4, 2026Phase 3 study in ObesityNCT07575399 · 300 planned · United States, Puerto Rico
- Jun 29, 20262 phase 3 studies in ObesityNCT07684235, NCT07684144
- Jul 16, 2026Phase 1 study in OverweightNCT07717814 · 154 enrolled · United States
- Sep 16, 2026Phase 1 study in OverweightNCT07832799 · 340 planned
- Oct 5, 20262 phase 3 studiesNCT07866066, NCT07871409
- Oct 27, 2026Phase 1 study in ObesityNCT07908316 · 180 planned · United States
- Nov 2, 2026Phase 1 study in ObesityNCT07921316 · 356 planned
Ahead
- Nov 15, 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 2NCT07160257
- Nov 18, 2026Primary completion: phase 1 study in OverweightNCT07523711
- Jan 21, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT06858878
- Jan 21, 2027Primary completion: phase 3 study in ObesityNCT06858839
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 32 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07921316Obesity | 1 | Not yet recruiting | Jul 26, 2027 | 356 |
| NCT07908316Obesity · United States | 1 | Recruiting | Dec 20, 2027 | 180 |
| NCT07871409Obesity · United States, Puerto Rico | 3 | Recruiting | Jun 16, 2027 | 230 |
| NCT07866066Diabetes Mellitus, Type 2 · United States, Canada | 3 | Recruiting | Sep 6, 2028 | 1,300 |
| NCT07832799Overweight | 1 | Not yet recruiting | Mar 23, 2027 | 340 |
| NCT07717814Overweight · United States | 1 | Completed | May 22, 2025 | 154 |
| NCT07684235Obesity · United States, Australia, Canada and more | 3 | Recruiting | Dec 26, 2027 | 3,200 |
| NCT07684144Obesity · United States, Canada, Japan and more | 3 | Recruiting | Dec 26, 2027 | 950 |
| NCT07575399Obesity · United States, Puerto Rico | 3 | Recruiting | Jan 3, 2028 | 300 |
| NCT07523711Overweight · United States | 1 | Active, not recruiting | Nov 18, 2026 | 49 |
| NCT07428525Liver Diseases · United States | 1 | Completed | Feb 26, 2026 | 36 |
| NCT07429045Overweight · United States | 1 | Completed | Nov 21, 2025 | 44 |
| NCT07429032Overweight · United States | 1 | Completed | Nov 26, 2025 | 57 |
| NCT07441252Overweight · United States | 2 | Active, not recruiting | Aug 25, 2027 | 180 |
| NCT07313761Overweight · United States | 1 | Completed | Jul 2, 2026 | 349 |
| NCT07310563Overweight · United States | 1 | Completed | May 9, 2025 | 59 |
| NCT07229157Overweight · United States | 1 | Completed | Aug 27, 2026 | 81 |
| NCT07226778Overweight · United States | 1 | Completed | May 28, 2026 | 348 |
| NCT07226765Sleep Apnea, Obstructive · United States, Australia, Brazil and more | 3 | Active, not recruiting | Aug 30, 2027 | 250 |
| NCT07225686Obesity · United States, Australia, Brazil and more | 3 | Active, not recruiting | Aug 20, 2027 | 250 |
| NCT07160257Diabetes Mellitus, Type 2 · United States | 1 | Active, not recruiting | Nov 15, 2026 | 56 |
| NCT07037459Obesity · United States, Argentina, Australia and more | 3 | Recruiting | Jun 30, 2028 | 5,056 |
| NCT07037433Atherosclerosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jun 30, 2028 | 12,800 |
| NCT06976372Overweight · United States | 1 | Completed | Dec 27, 2024 | 120 |
| NCT06987695Overweight · Japan | 3 | Active, not recruiting | Apr 27, 2027 | 279 |
| NCT06858878Diabetes Mellitus, Type 2 · United States, Argentina, Bulgaria and more | 3 | Active, not recruiting | Jan 21, 2027 | 1,105 |
| NCT06858839Obesity · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 21, 2027 | 3,853 |
| NCT06660173Diabetes Mellitus, Type 2 · United States, Austria, Greece and more | 2 | Active, not recruiting | Oct 6, 2025 | 409 |
| NCT06352892Obesity · Hong Kong | 1 | Completed | Aug 27, 2024 | 20 |
| NCT05669599Obesity · United States, Australia, Canada and more | 2 | Completed | Oct 8, 2024 | 592 |
| NCT05056246Healthy Participants · United States | 1 | Completed | Apr 8, 2022 | 34 |
| NCT04478708Obesity · United States | 1 | Completed | Nov 18, 2022 | 110 |
How it is read
Names in the registry
- “Maridebart cafraglutide”, 12 entries
- “Maridebart Cafraglutide”, 12 entries
- “AMG 133”, 6 entries
- “AMG 133 (frozen liquid)”, 1 entry
- “AMG 133 (liquid)”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 23 studies
- Diabetes Mellitus, Type 2, 4 studies
- Atherosclerosis, 1 study
- Sleep Apnea, Obstructive, 1 study
- Liver Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.